Health knowledge made personal
Join this community!
› Share page:
Search posts:

Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Posted Feb 20 2013 7:00pm

Description of Invention:
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction. This is a promising new therapeutic approach known as adoptive cell therapy.

CD22 is a cell surface protein that is expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma. Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins. This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.

  • Treatment of diseases associated with increased or preferential expression of CD22
  • Specific diseases include hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)

  • High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting
  • Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients
  • Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream
  • Expression of CD22 only on mature cells allows the avoidance of stem cell elimination during treatment

Development Status:

Dimiter S Dimitrov (NCI)
Ira H Pastan (NCI)
Rimas J Orentas (NCI)
Crystal L Mackall (NCI)

Patent Status:
HHS, Reference No. E-291-2012/0
US, Application No. 61/717,960 filed 24 Oct 2012

Related Technologies:
US, Application No. 12/934,214 filed 23 Sep 2010, Reference No. E-080-2008/0
US, Application No. 61/042,329 filed 04 Apr 2008, Reference No. E-080-2008/0

For Licensing Information Please Contact:
David Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-4632
Fax: 301-402-0220

Ref No: 2534

Updated: 02/2013

Post a comment
Write a comment:

Related Searches